OSUR · OraSure Technologies, Inc.

OraSure’s Q1 2026 results reflect a deliberate pivot toward its core diagnostics and sample management businesses amid the wind-down of pandemic-related revenue streams. Total revenue declined 7% year-over-year to $27.9 million, but core business revenue held nearly flat at $27.9 million—down just 0.5%—with Diagnostics falling 5% to $16.9 million (driven by lower HCV test demand) and Sample Management Solutions dipping 0.6% to $9.1 million. The company achieved meaningful gross margin expansion: GAAP gross margin rose to 42.3% from 41.1%, and Non-GAAP gross margin increased to 43.4% from 41.7%, underscoring progress on manufacturing efficiencies and cost discipline. However, operating loss widened to $23.3 million (GAAP) from $17.8 million, reflecting sustained R&D investment ($13.7M, up 42% YoY) and ongoing transformation initiatives—including organizational right-sizing, footprint consolidation, and multi-year innovation planning. Management highlighted stable demand in key segments, improved visibility into public funding for testing programs, and near-term catalysts including FDA regulatory reviews for new urine and blood self-collection products. With $177 million in cash, no debt, and $20 million of its $40 million share buyback authorization already deployed, OraSure maintains financial flexibility to fund both internal R&D and strategic M&A. Its Q2 guidance of $27–30 million signals cautious optimism around core growth reacceleration, while reaffirming that Non-GAAP gross margin will remain stable near 43.4%—a stepping stone toward the stated long-term target of 50%.